News
QNRX
3.560
+5.95%
0.200
Weekly Report: what happened at QNRX last week (1109-1113)?
Weekly Report · 2d ago
Quoin Pharmaceuticals Shareholders Approve Beneficial Ownership Limit Changes
TipRanks · 5d ago
Canaccord Genuity Keeps Their Buy Rating on Quoin Pharmaceuticals (QNRX)
TipRanks · 11/09 12:56
Weekly Report: what happened at QNRX last week (1102-1106)?
Weekly Report · 11/09 10:12
Quoin Pharmaceuticals, Ltd. Reports Third Quarter 2026 Financial Results
NASDAQ · 11/07 02:58
Maxim Group Remains a Buy on Quoin Pharmaceuticals (QNRX)
TipRanks · 11/06 18:45
Quoin Therapeutics: Encouraging QRX003 Results and Regulatory Progress Support Buy Rating; $14 Price Target Maintained
TipRanks · 11/06 14:33
Quoin Pharmaceuticals GAAP EPS of -$0.97
Seeking Alpha · 11/05 17:49
Quoin Pharmaceuticals Q3 EPS $(0.97) Beats $(1.52) Estimate
Benzinga · 11/05 13:31
Quoin Pharmaceuticals Enters Agreement for At-the-Market ADS Offering
TipRanks · 11/04 23:38
12 Health Care Stocks Moving In Monday's After-Market Session
Benzinga · 11/02 21:05
Weekly Report: what happened at QNRX last week (1026-1030)?
Weekly Report · 11/02 10:11
Quoin Pharmaceuticals files $150M mixed securities shelf
TipRanks · 10/28 10:10
Weekly Report: what happened at QNRX last week (1019-1023)?
Weekly Report · 10/26 10:11
Quoin Showcases QRX003 Pediatric Data in Published Study
TipRanks · 10/20 10:57
Quoin Pharma Announces Publication Of Peer-Reviewed Paper Introducing QRX003 And Its Mechanism Of Action In Netherton Syndrome
Benzinga · 10/20 10:36
Quoin Pharmaceuticals Price Target Announced at $18.00/Share by Canaccord Genuity
Dow Jones · 10/19 12:23
Canaccord Genuity Initiates Coverage On Quoin Pharmaceuticals with Buy Rating, Announces Price Target of $18
Benzinga · 10/19 12:14
Weekly Report: what happened at QNRX last week (1012-1016)?
Weekly Report · 10/19 10:11
Quoin Pharmaceuticals initiated with a Buy at Canaccord
TipRanks · 10/19 09:35
More
Webull provides a variety of real-time QNRX stock news. You can receive the latest news about Quoin Pharmaceuticals Ltd through multiple platforms. This information may help you make smarter investment decisions.
About QNRX
Quoin Pharmaceuticals Ltd, former Cellect Biotechnology Ltd, is an Israel-based specialty pharmaceutical company, focused on developing and commercializing therapeutic products that treat rare and orphan diseases. The Company’s first lead product is QRX003, a once daily, topical lotion comprised of a broad-spectrum serine protease inhibitor, formulated with the proprietary Invisicare technology, to treat Netherton Syndrome. The product going to be developed for other rare dermatological diseases including Peeling Skin Syndrome, SAM Syndrome, and Palmoplantar Keratoderma. Quoin is also developing QRX004 as a potential treatment for Dystrophic Epidermolysis Bullosa, and QRX006 as a potential therapy for an, as of yet, undisclosed rare skin disease.